AHA Statement on Heart Failure and Polypharmacy

Video

VIDEO: In a Medical News Minute, a topline review of the AHA's comprehensive guide to risk reduction in HF patients.

Heart failure (HF) is the leading diagnosis at hospital discharge among patients age ≥65 years. On average HF patients take 6.8 prescriptions a day and the majority also take over the counter and complimentary/alternative medications (CAM). Combined with the often complex dosing schedules for prescription medications, these regimens put older patients at high risk for drug-drug interactions, direct myocardial toxicity-or both.

In this Medical News Minute, Dr Bobby Lazzara reviews a recent scientific statement from the American Heart Association on pharmaceutical agents that may directly cause or exacerbate heart failure. The statement includes a compendium of agents from analgesics and anticancer meds to urologic and QT-interval prolonging medications that may cause or exacerbate heart failure. It also includes several tables of CAM that may be harmful in HF or have significant interactions with HF drugs.

Source: Page RL, O'Bryant CL, Cheng D, et al and on behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation.2016;134. http://dx.doi.org/10.1161/CIR.0000000000000426 

 

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.